Applications of Patient-Specific Induced Pluripotent Stem Cells; Focused on Disease Modeling, Drug Screening and Therapeutic Potentials for Liver Disease by Chun, Yong Soon et al.
Int. J. Biol. Sci. 2010, 6 
 
 
http://www.biolsci.org 
796 
I In nt te er rn na at ti io on na al l   J Jo ou ur rn na al l   o of f   B Bi io ol lo og gi ic ca al l   S Sc ci ie en nc ce es s   
2010; 6(7):796-805 
© Ivyspring International Publisher. All rights reserved 
Review 
Applications of Patient-Specific Induced Pluripotent Stem Cells; Focused on 
Disease Modeling, Drug Screening and Therapeutic Potentials for Liver 
Disease 
Yong Soon Chun, Pooja Chaudhari, Yoon-Young Jang 
 
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA  
 Corresponding author: Yoon-Young Jang, M.D., Ph.D., Stem Cell Biology laboratory, Department of Oncology, Johns 
Hopkins University School of Medicine,  1550 Orleans Street, CRB2 Rm552, Baltimore, MD 21231. Office (410) 502-8195; 
Email: yjang3@jhmi.edu 
Received: 2010.12.08; Accepted: 2010.12.13; Published: 2010.12.14 
Abstract 
The recent advances in the induced pluripotent stem cell (iPSC) research have significantly 
changed our perspectives on regenerative medicine by providing researchers with a unique 
t o o l   t o   d e r i v e   d i s e a s e -s p e c i f i c   s t e m   c e l l s   f o r   s t u d y .   I n   t h i s   r e v i e w ,   w e   d e s c r i b e   t h e   h u m a n   i P S C  
generation from developmentally diverse origins (i.e. endoderm-, mesoderm-,   a n d   e c t o d e r m - 
tissue derived human iPSCs) and multistage hepatic differentiation protocols, and discuss both 
basic and clinical applications of these cells including disease modeling, drug toxicity screen-
ing/drug discovery, gene therapy and cell replacement therapy. 
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Introduction 
In 2006, Yamanaka and co-workers first reported 
the  generation  of  induced  pluripotent  stem  cells 
( i P S C s )   f r o m   m o u s e   s o m a t i c   f i b r o b l a s t s   b y   t h e   r e t r o-
viral transduction of Oct4, Sox2, Klf4 and c-Myc genes 
(1). Subsequently, human iPSCs have been generated 
from embryonic, neonatal and adult fibroblasts (2-4). 
In addition, derivation of patient-specific  iPSCs  for 
various  diseases/disorders  has  also  been  reported 
(5-9). More recently several groups have explored the 
possibilities  of  disease  modeling  using  patient  de-
rived iPSCs and directed differentiation technologies 
(7, 10-1 8 ) .   S i n c e   i P S C s   r e s e m b l e   e m b r y o n i c   s t e m   c e l l s  
(ESCs) in their pluripotency, and offer potential solu-
tions for histo-incompatibility issues that limit the use 
of  ESC-based  therapies,  patient-specific  iPSCs  hold 
great potential as an unlimited cell source not only for 
generating  disease  models  but  also  drug  screening 
and cell replacement therapy for various diseases.  
One  of  the  main  hurdles  for  achieving  these 
goals is to develop efficient directed differentiation 
technologies that are also functional and safe. During 
recent years, in vitro hepatic differentiation from both 
h u m a n   E S C s   a n d   i P S C s   h a s   b e e n   a c h i e v e d   a n d   i m-
proved  by  several  laboratories  including  ours  (15, 
19-22). For patients with end-stage liver disease, liver 
transplantation is the only curative method of treat-
ment (23). However, limited availability of donor liv-
ers  and  immunological  incompatibilities  are  major 
obstacles  to  liver  or  hepatocyte  transplantation  (24). 
T h e   u s e   o f   ex vivo adult human hepatocytes is a de-
s i r a b l e   o p t i o n   f o r   c e l l u l a r   t h e r a p i e s   o r   d r u g   t e s t i n g .  
However,  these  cells  have  limited  proliferation  po-
tential, and lose function and viability upon isolation. 
Although  there  have  been  great  advances  in  liver 
stem cell biology (25-27), adult liver stem cells are rare 
within tissue, making their isolation difficult and ex-
pansion unfavorable for large-scale applications (28). 
Therefore it is critical to develop alternative strategies 
such as iPSC derived functional hepatic cells  as an 
u n l i m i t e d   h e p a t o c y t e   s o u r c e   w h i c h   c a n   b e   u t i l i z e d   i n  Int. J. Biol. Sci. 2010, 6 
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drug screening, disease modeling and cell therapy. In 
this review, we summarize the current progress in the 
field of human iPSCs and hepatic differentiation, and 
discuss  both  basic  and  clinical  applications  of  the 
iPSCs with an emphasis on liver disease. 
Technical advances in iPSC derivation me-
thods 
Most  patient-specific  iPSCs  have  been  estab-
lished using retrovirus vectors. However, the retro-
v i r a l l y   d e r i v e d   i P S C s   c a r r y   t h e   r i s k   o f   n u m e r o u s  
transgene integrations in the genome, which may re-
sult in leaky expression. This could disturb the endo-
genous transcription factor network and lead to fail-
ure of directed differentiation.  Also,  transgene  inte-
gration has a risk of tumorigenesis after transplanta-
t i o n .   I n   p a r t i c u l a r ,   c -M y c ,   o n e   o f   t h e   r e p r o g r a m m i n g  
factors, is a well-known oncogene, and its reactivation 
could give rise to transgene driven-tumor formation 
( 2 9 ) .   T h e r e   h a v e been several reports of improvements 
o f   t h e   t r a n s d u c t i o n   m e t h o d   f o r   g e n e r a t i n g   s a f e   i P S C s .  
Removal of the c-Myc transgene from reprogramming 
cocktail  is  one  important  approach.  Human  and 
m o u s e   i P S C s   h a v e   b e e n   e s t a b l i s h e d   f r o m   f i b r o b l a s t s  
w i t h   o n l y   O c t 4 ,   Sox2, and Klf4, although the efficiency 
is  significantly  reduced  (30).  Other  different  ap-
proaches have also been devised to introduce repro-
gramming  factors  into  somatic  cells  (Table  1).  A 
transposon  system  encoding  a  reprogramming  cas-
sette has been used for iPSC induction (31, 32). The 
transduction  of  a  plasmid-based  transposon  vector 
enables it to integrate into the host genome with the 
h e l p   o f   t r a n s p o s a s e ,   a n d   i n d u c e s   i P S C   c o l o n y   f o r m a-
tion. The re-expression of the transposase recognizes 
the terminal repeat of the integrated transposon vec-
tor, and excises it from the genome. The excision of 
t h e   t r a n s p o s o n   d o e s   n o t   l e a v e   a   f o o t p r i n t   i n   m o s t  
cases, and hence maintains the original endogenous 
sequence. Several other methods accomplished iPSC 
induction  by  the  transient expression of reprogram-
ming  factors.  These  methods  include  viral  vectors 
(adenovirus and Sendai virus) (33, 34), DNA vectors 
( p l a s m i d   a n d   e p i s o m a l   p l a s m i d   v e c t o r )   ( 3 5 ,   3 6 ) ,   s m a l l  
molecules  (37),  and  direct  protein  delivery  (38). 
However, the efficiency of most of these integration 
free iPSC induction systems is significantly lower than 
that with retrovirus vectors. More recently, the Rossi 
group  used  synthetic  mRNA  to  reprogram  human 
f i b r o b l a s t s   t o   p l u r i p o t e n c y   a n d   i n d u c e d   d i f f e r e n t i a-
tion  terminall y   i n t o   m y o g e n i c   c e l l s   ( 3 9 ) .   T h e   u s e   o f  
synthetic mRNA overcomes the innate antiviral res-
ponses,  and  showed  superior  conversion  efficiency 
and kinetics than the established viral protocols. Al-
though  relatively  technically  complex,  synthetic 
mRNA completely eliminates the risk of genomic in-
tegration and thus insertional mutagenesis inherent to 
all  DNA-based methodologies. Also, the potential of 
temporal control over the individual factor expression 
a f f o r d e d   b y   t h i s   s y s t e m   c o u l d   h e l p   t o   e l u c i d a t e   t h e  
stage-specific roles of individual transcription factors 
during reprogramming.  
 
Table 1.  Integration-free human iPSC induction methods 
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Generation of Human iPSCs from Different 
Somatic Cell Types 
O n e   o f   t h e   m o s t   i m p o r t a n t   i s s u e s   t o   b e   a d-
d r e s s e d   b e f o r e   h u m a n   i P S C s   c a n   b e   u s e d   f o r   c l i n i c a l  
p u r p o s e s   i s   t h e   g e n e r a t i o n   o f   s a f e   a n d   f u n c t i o n a l   c e l l  
types for therapy. Embryonic fibroblasts and tail-tip 
fibroblasts in the mouse and dermal fibroblasts in the 
h u m a n   h a v e   b e e n   t h e   m o s t   w i d e l y   u s e d   c e l l   t y p e s   f o r  
reprogramming, largely due to their availability and 
relative ease of culture. A comprehensive study using 
v a r i o u s   m o u s e   i P S C s   h a s   d e m o n s t r a t e d   t h a t   t h e   o r i g i n  
of  the  iPSCs  has  a  profound  influence  o n   t h e   t u-
mor-forming  propensities  in  a  cell  transplantation 
therapy  model  (40).  Mouse  tail-tip  fibroblast  iPSCs 
(mesoderm  origin)  have  shown  the  highest  tumori-
genic propensity, whereas gastric epithelial and he-
p a t o c y t e   d e r i v e d   i P S C s   ( b o t h   w i t h   e n d o d e r m a l   origin) 
have shown significantly lower tumorigenic propen-
sities (40). The molecular mechanism underlying this 
p h e n o m e n o n   i s   n o t   y e t   f u l l y   u n d e r s t o o d ,   b u t   e v i d e n c e  
suggests that epigenetic memory of the somatic cell of 
o r i g i n   i s   r e t a i n e d   i n   t h e   i P S C s ,   a n d   t hat the memory 
may influence their directed differentiation potential 
into blood cells (41, 42).  
Based upon these mouse iPSC studies, it is rea-
s o n a b l e   t o   s p e c u l a t e   t h a t   t h e   s o m a t i c   m e m o r y   o f   h u-
man iPSCs might have an effect on their differentia-
t i o n   p o t e n t i a l ,   w h i c h   i s   c r i t i c a l   f o r   d i s e a s e   m o d e l i n g  
and therapy. A l t h o u g h   i t   h a s   b e e n   d e m o n s t r a ted that 
human iPSCs retain certain gene expression patterns 
o f   t h e   p a r e n t   c e l l s   ( 4 3 ) ,   i t   r e m a i n s   l a r g e l y   u n c l e a r   i f   t h e  
cell origin could affect the safety and functionality of 
human iPSCs. It is therefore extremely important to 
establish  human  iPSC  lines  from  different  develop-
mental  origins  and  thoroughly  examine  the  source 
that  might  affect  both  the  safety  aspects  and  their 
differentiation  potentials.  Human  iPSCs  have  been 
derived mostly from the mesodermal (i.e. fibroblasts 
a n d   b l o o d   c e l l s )   o r   t h e   e c t o d ermal  origin  cells  (i.e. 
keratinocytes, and neural stem cells) (Table 2).  
 
Table 2. Human iPSCs derived from different somatic cell types 
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We have recently shown the reprogramming of 
human primary hepatocytes (i.e. endodermal origin) 
i n t o   i P S C s   ( 2 2 )   ( T a b l e   2 ) .   T h e   t e c h n o l o g y   t o   d e v e l o p  
human endoderm tissue-derived iPSC lines, together 
with other established human iPSC lines, provides a 
f o u n d a t i o n   t o   e l u c i d a t e   t h e   m e c h a n i s m s   o f   c e l l u l a r  
reprogramming and study the safety and efficacy of 
differentially originated human iPSCs for cell therapy. 
F o r   s t u d y i n g   p a t h o g e n e s i s   o f   l i v e r   d i s e a s e ,   t h i s   t e c h-
nology  also  provides  a  potentially  more  amenable 
system to generate liver disease-specific iPSCs. The 
a b i l i t y   t o   r e p r o g r a m   h u m a n   h e p a t o c y t e s   i s   c r u c i a l   f o r  
developing  iPSC-based  liver  disease  models,  espe-
cially for certain liver disorders involving acquired 
s o m a t i c   m u t a t i o n s   t h a t   o c c u r   o n l y   i n   h e p a t o c y t e s   o f  
patients and not in other cell types (44-48).  
Recently, two groups have reported derivation 
o f   h u m a n   i P S C s   f r o m   m a l i g n a n t   c e l l   l i n e s   ( T a b l e   3 )  
demonstrating that these iPSCs lose certain cancer cell 
characteristics after reprogramming (49, 50). Howev-
er, it remains to be determined whether these cancer 
derived iPSCs still retain genetic/epigenetic memory 
o f   t h e   o r i g i n a l   c a n c e r   t i s s u e ;   a n d   m o r e   i m p o r t a n t l y   i f  
t h e s e   i P S C s   c a n   b e   u t i l i z e d   f o r   d i s e a s e   m o d e l i n g ,   i n  
order to study complicated cancer pathogenesis and 
d r u g   s c r e e n i n g   p u r p o s e s .   I n   t h i s   r e g a r d ,   i t is valuable 
to  establish  multiple  cancer-derived iPSC lines, pre-
ferably  from  primary  tumors  and  comprehensively 
evaluate their disease modeling potentials.   
Table 3. Human iPSCs derived from cultured human malignant cell lines 
 
 
Hepatic Differentiation of human iPSCs 
Directed differentiation of human iPSC lines into 
hepatic cells has been improved with more efficient 
and  functional  methods  including  our  multistage 
differentiation protocol (19, 21, 22, 48, 51). Our step-
wise hepatic differentiation protocol is composed of 
three  differentiative  stages  resembling  liver  devel-
opment, i.e. definitive endoderm, hepatic progenitors, 
and mature hepatocytes (22, 48). This iPSC based he-
patic  differentiation technology holds great promise 
a s   a n   u l t i m a t e   h e p a t o c y t e   s o u r c e   w h i c h   c a n   b e   u t i-
lized for drug screening, disease modeling and cell 
therapy,  however,  more  research is  required  to im-
prove their function. The functionality of human iPSC 
derived mature hepatocytes can be analyzed in vitro, 
by various methods, including analyses for cytoch-
rome P-450 activity and glycogen storage ability with 
the Periodic Acid-Schiff assay (22). Although these in 
vitro methods are highly informative and convenient, 
the most   d e f i n i t i v e   p r o o f   f o r   t h e   f u n c t i o n a l i t y   o f   h u-
man iPSC derived hepatic cells would be the demon-
stration  of  hepatic  engraftment  in vivo using  animal 
models  (48)  and  detection  of  secreted  human  liver 
proteins in animal serum/plasma.  
A  recent  study  demonstrated  the  feasibility  of 
using  in  vitro hepatic differentiation of human iPSCs 
t o   m o d e l   s e v e r a l   i n h e r i t e d   l i v e r   d i s e a s e s   ( 1 5 ) .   A l-
though  the  in  vitro  culture  may  recapitulate  certain 
d i s e a s e   f e a t u r e s   a n d   m a y   b e   s u i t a b l e   f o r   d r u g   s c r e e n-
ing  purposes,  successful  regenerative  therapy  will 
require hepatic cells that can functionally engraft the 
l i v e r .   T o   d a t e ,   t h e   in vivo functionality of human iPSC 
d e r i v e d   h e p a t i c   c e l l s   i s   l a r g e l y   u n k n o w n   ( 4 7 ,   5 0 ) .  
Therefore, it remains to be determined whether the 
human iPSC -derived multistage hepatic cells possess 
in vivo functional activities and which differentiative 
stage  of  hepatic  cells  is  most  suitable  for  efficient, 
functional and safe regeneration of the injured liver. 
Disease modeling with human iPSCs 
The concept of utilizing iPSCs to model a disease 
i n   a   c u l t u r e   d i s h   i s   b a s e d   o n   t h e   u n i q u e   c a p a c i t y   o f  
these cells to continuously self-renew  and  their  po-
tential to give rise to all cell types in human body. The 
greatest advantage of iPSC technology is that it allows Int. J. Biol. Sci. 2010, 6 
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for the   g e n e r a t i o n   o f   p l u r i p o t e n t   c e l l s   f r o m   a n y   i n d i-
v i d u a l   i n   t h e   c o n t e x t   o f   h i s   o r   h e r   o w n   p a r t i c u l a r   g e-
netic  identity,  including  individuals  with  sporadic 
f o r m s   o f   d i s e a s e ;   a n d   t h o s e   a f f e c t e d   b y   c o m p l e x   m u l-
tifactorial diseases of unknown genetic identity, such 
as type 1 diabetes (52) and liver cancers (44-48).  
Recently, a number of studies have reported the 
successful  generation  of  patient-specific  iPSC  lines 
from  individuals  with  different  diseases;  however, 
effective disease modeling has been demonstrated on 
a few studies (Table 4). For example, Ebert et al. re-
ported  the  differentiation  of  iPSC-derived  motor 
neurons from a patient diagnosed with a genetic from 
o f   s p i n a l   m u s c u l a r   a t r o p h y   ( S M A ) ,   a   n e u r o d e g e n e r a-
t i v e   d i s e a s e   t h a t   l e a d s   t o   l o s s   o f   l o w e r   m o t o r   n e u rons 
( 1 1 ) .   A l t h o u g h   m o t o r   n e u r o n s   d e r i v e d   f r o m   t h e   p a-
tient-specific  iPSCs  were  initially  similar  in  mor-
phology and number, to those derived from wild-type 
iPSCs,  their  numbers  and  size  selectively  declined 
after eight weeks in culture. Furthermore, these cells 
exhibited a deficiency in the survival of motor neuron 
(SMN)  protein  aggregates,  which  is  a  characteristic 
phenotype  associated  with  SMA.  Importantly,  this 
deficiency in SMN levels could possibly be reversed 
with drug treatment, thus providing a basis for future 
drug screens.  
G e n e r a t i o n   o f   l i v e r   d i s e a s e   p a t i e n t   i P S C s   h a s   r e-
cently  been  reported  from  patients  who  have  inhe-
rited  liver  diseases  that  arise  as  a  result  of  loss  of 
function  mutation  ( 1 5 ,   1 6 ) .   B y   f o c u s i n g   o n   a   r e p r e-
sentative disease for each of the different mechanisms 
in liver diseases such as protein misfolding, cell sur-
face receptor dysfunction and obstruction of cytosolic 
m e t a b o l i s m ,   a n d   g e n e r a t i n g   i P S C   l i n e s   t h a t   s u c c e s s-
fully recapitulate cellular pathological features in vi-
tro;   i t   i s   n o w   p l a u s i b l e   t h a t   i P S C   t e c h n o l o g y   c a n   b e  
u s e d   t o   m o d e l   o t h e r   d i s e a s e s   i n v o l v i n g   t h e s e   m e-
chanisms  (Table  4).  Importantly,  this  demonstrates 
that subtle intracellular processes can be studied in an 
in vitro cellular system, and that they can be accurately 
preserved despite the high stress exerted on cells by 
the reprogramming and differentiation protocols.  
While  the  generation  of  disease-specific  iPSC 
lines is a critical first step, ultimately, it will be ne-
cessary to derive a representative set of human iPSCs 
from different patients; as the phenotype and severity 
o f   m a n y   o f   t h e s e   d i s e a s e s   c a n   v a r y   m a r k e d l y   w i t h i n  
the population. Of note, even though some of these 
non-h e p a t i c   s o u r c e d   i P S C s   c o u l d   b e   s u f f i c i e n t   f o r   r e-
generation therapy and drug screening for many liver 
disorders  including  inherited  diseases,  hepat-
ic-s o u r c e d   i P S C s   w i l l   s t i l l   b e   r e q u i r e d   f o r   d i s e a s e  
modeling of certain acquired liver diseases such as 
cirrhosis and hepatocellular carcinoma.  
Drug toxicity screening and drug discovery 
using human iPSCs 
T h e   a v a i l a b i l i t y   o f   h u m a n   i P S C s   o f f e r s   e x c i t i n g  
opportunities  for  reliable  high  throughput  drug 
s c r e e n i n g .   T h e   a b i l i t y   t o   u s e   h u m a n   c e l l   t y p e s   i n   t o x-
icology studies has the potential to increase the effi-
ciency  of  novel  drug  development,  while  reducing 
drug   a t t r i t i o n   i n   t h e   f i n a l   s t a g e s   o f   d e v e l o p m e n t   a n d  
c o s t s .   A d d i t i o n a l l y ,   t h e   u s e   o f   h u m a n   i P S C s   w o u l d  
also enable the study of a number of single nucleotide 
p o l y m o r p h i s m s   t h a t   i n f l u e n c e   t h e   a b i l i t y   o f   a n   i n d i-
vidual to effectively metabolize and clear drugs and 
toxins. Accurate prediction of human drug toxicity is 
a   v i t a l   e l e m e n t   o f   d r u g   d i s c o v e r y   p r o c e s s .   I n   p a r t i c u-
lar, hepatotoxicity and cardiotoxicity are two princip-
al causes of drug failure during preclinical testing, 
while the variability in individual responses  to  po-
tential therapeutic agents is also a major problem in 
effective drug development (53). However the safety 
e v a l u a t i o n   p r o c e s s   i s   h i n d e r e d   b y   t h e   a v a i l a b i l i t y   a n d  
quality of primary human liver models with which to 
study drug toxicity. Developme n t   o f   t h e   s c a l a b l e   a n d  
high-fidelity human hepatocytes from fetal and adult 
progenitors has been hindered due to limited organ 
availability, and rapid loss of hepatocyte function in 
c u l t u r e .   T h e   a d v a n t a g e   o f   i P S C   t e c h n o l o g y   i s   t h a t   i t  
allows the generation   o f   a   l i b r a r y   o f   h u m a n   c e l l   l i n e s  
that may represent the genetic and potentially epige-
n e t i c   v a r i a t i o n   o f   a   b r o a d   s p e c t r u m   o f   t h e   p o p u l a t i o n .  
T h e   u s e   o f   t h i s   t o o l   i n   h i g h -throughput screening as-
says could allow better prediction of the toxicology 
and  therapeutic responses induced by newly devel-
o p e d   d r u g s ,   a n d   o f f e r   i n s i g h t   i n t o   t h e   u n d e r l y i n g  
m e c h a n i s m s .   T h e   n e t   r e s u l t   o f   t h i s   a p p r o a c h   w o u l d  
substantially  decrease  the  risk  and  cost  associated 
with early-s t a g e   c l i n i c a l   t r i a l s   a n d   c o u l d   l e a d   t o w a r d   a  
more personalized approach in drug administration. 
Because iPSCs grow indefinitely in culture, they pro-
vide an unlimited resource of any desired specialized 
cells. Ultimately, the goal of this approach is to use 
patient iPSC based disease models to identify novel 
d r u g s   t o   t r e a t   t h e   d i s e a s e .   I n   o r d e r   t o   d e t e r m i n e   i n d i-
vidual drug effects on disease specific iPSC derived 
functional  cell  types  (e.g    hepatocytes  differentiated 
from alpha 1 antitrypsin deficiency patient iPSCs), the 
disease phenotypes needs to be consistently and un-
iformly  recapitulated.  Although  there  have  been 
m a n y   a t t e m p t s   t o   d e r i v e   p a t i e n t   s p e c i f i c   i P S C s ,   o n l y   a  
few reports have demonstrated some of the disease 
f e a t u r e s   w i t h   v a r i a b l e   d e g r e e s   ( T a b l e   4 ) .   I t   r e m a i n s ,  
however, to further develop disease modeling condi-
tions and optimize differentiation conditions for more 
accurate disease modeling and drug screening. Int. J. Biol. Sci. 2010, 6 
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Table 4. List of current disease-specific iPSC lines 
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Therapeutic Potentials of human iPSCs  
A n   u l t i m a t e   g o a l   f o r   i P S C   r e s e a r c h   w i l l   b e   t o   u s e  
the iPSC (generation and differentiation) technology 
for  therapy.  Because  iPSCs  can  bypass  the  ethical 
concerns  related  to  ESC  derivation  and  potential  is-
sues of allogenic rejection, they may represent a more 
i d e a l   s o u r c e   t o   p r o d u c e   p a t i e n t -specific  and  dis-
ease-specific adult cells for future clinical applications 
and drug development. Organ transplantation among 
non-related  individuals  is  also  complicated  by  the 
limited   a v a i l a b i l i t y   o f   m a t c h e d   t i s s u e s   a n d   t h e   r e-
quirement for life-long  treatment  with  immunosup-
pressive  drugs  that  can  have  serious  side  effects. 
Human  iPSCs  might  potentially  circumvent  these 
problems, as they could be coaxed into the desired cell 
types that would already be genetically matched with 
the patient.  
A n o t h e r   k e y   a d v a n t a g e   o f   i P S C s   o v e r   c u r r e n t  
transplantation  approaches  is  the  possibility  of  re-
pairing disease-causing  mutations  by  gene  targeting 
and correction technologies. A proof of principle that 
i P S C s   c a n   b e   u s e d   t o   t r e a t   d i s e a s e   b y   c o r r e c t i o n   o f   t h e  
underlying  genetic  defect  was  demonstrated  in  a 
m o u s e   m o d e l   o f   s i c k l e   c e l l   a n e m i a   ( 5 4 ) .   T h e   w i l d -type 
β-globin gene was used to replace the defective gene 
by  homologous  recombination.  Remarkably,  trans-
plantation  with  genetically  corrected  iPSC-derived 
hematopoietic  progenitors  was  successful  in  ameli-
orating  the  symptoms  of  anemia  and  for  restoring 
physiological  function  in  the  diseased  animal.  In 
principle, this approach could be applied to any dis-
ease in humans for which the underlying mutation is 
k n o w n ,   a n d   t h a t   c a n   b e   t r e a t e d   b y   c e l l   t r a n s p l a n t a t i o n .  
A similar approach was taken with human individu-
als with Fanconi anemia, a disease characterized by 
severe genetic instability (8). In this case, the mutant 
gene  was  replaced  using  lentiviral  vectors  prior  to 
epigenetic reprogramming of the patient’s fibroblasts 
and  keratinocytes,  as  the  genetic  instability  of  the 
mutant  fibroblasts  made  them  non-permissive  for 
iPSC  generation.  Importantly,  these  iPSCs  could  be 
differentiated into hematopoietic progenitors as effi-
ciently  as  wild-type  iPSCs,  stably  maintaining  the 
disease-free phenotype in vitro.  
Hepatocytes are the main functional cells of the 
l i v e r   a n d   p e r f o r m   a   v a r i e t y   o f   i m p o r t a n t   e n d o c r i n e  
and  exocrine  functions.  Research  employing  human 
hepatocytes for cellular transplantation has been con-
strained by the difficulties in sourcing and maintain-
ing  viable  hepatocytes.  A  number  of  innovative 
cell-b a s e d   a n d   a n i m a l   m o d e l   s t u d i e s   o f   h u m a n   l i v e r  
disorders have highlighted the remarkable regenera-
tive  capacity  of  hepatocytes  in vivo,  indicating  the 
feasibility of hepatocyte transplantation as a means of 
r e p l a c i n g   l o s t   o r   d i s e a s e d   h e p a t i c   t i s s u e   ( 5 5 -58). 
Transplantation of hepatocytes derived from human 
iPSCs  could  represent  an  alternative  either  to  liver 
t r a n s p l a n t a t i o n   i n   a c u t e   l i v e r   f a i l u r e   o r   f o r   t h e   c o r r e c-
tion  of  genetic  disorders  resulting  in  metabolically 
deficient states (59).  
 
Conclusion 
Since  the  first  description  of  iPSC  generation, 
there has been remarkable progress toward basic and 
clinical  implementation  of  the  iPSC  technologies 
(Figure 1). However, several key issues remain to be 
addressed  for  more  accurate  disease  modeling  and 
t h e r a p y ;   f i r s t ,   p a t i e n t   s p e c i f i c   i P S C s   n e e d s   t o   b e   d e r i-
vated  from  diseased  tissue  portions  (i.e.  hepatocyte 
within liver cancer) rather than the tissues which do 
not carry any pathogenetic events (i.e. skin fibroblasts 
for liver cancer). Second, major challenges also remain 
in directed differentiation protocols and disease reca-
pitulation  technologies  that  efficiently  lead  to  pure 
and functional populations of many disease-relevant 
c e l l   t y p e s   f o r   t h e   p u r p o s e   o f   d i s e a s e   m o d e l i n g   a n d  
drug screening. Finally, extensive characterization of 
the  functionality  of  iPSC-derived  somatic  cells  and 
their functional equivalence with in vivo counterparts 
n e e d s   t o   b e   d e m o n s t r a t e d   a l o n g   w i t h   t h e   s a f e t y   f o r   t h e  
future regeneration therapy. Given the rapid pace of 
developments within the iPSC field, it is likely that the 
generation of safe and effective iPSCs for use in cell 
t h e r a p y   a s   w e l l   a s   i n   d i s e a s e   m o d e l i n g   a n d   d r u g  
screening will be achieved in the near future. Int. J. Biol. Sci. 2010, 6 
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Figure 1. Potential applications of human iPSCs for liver diseases. iPSC technology can be potentially utilized in 
disease modeling, pathogenesis research, drug discovery, gene therapy and cell replacement therapy. Genetic mutations can 
b e   c o r r e c t e d   b y   g e n e   t a r g e t i n g   a p p r o a c h e s   b e f o r e   o r   a f t e r   r e p r o g r a m m i n g .   H e p a t i c   c e l l s   d i f f e r e n t i a t e d   f r o m   p a t i e n t specific 
iPSCs can be used for disease modeling and transplantation purposes. 
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